RocketVax COVID-19 vaccine

23 December 2020

Serbian newspapers are reporting about RocketVax’s development of an effective and safe COVID-19 vaccine

The COVID-19 pandemic has led to a dramatic loss of human life worldwide and presents an unprecedented challenge to public health, food systems, and the world of work. The coronavirus is currently affecting 218 countries and territories around the world.

Therefore, the rapid development of an effective and safe vaccine against SARS-CoV-2 is a top priority for RocketVax. As a Basel-based subsidiary, RocketVax was founded to utilize innovative Swiss technologies and expertise to achieve this goal.

Serbia is one of the countries that have been badly affected by pandemics. Therefore, Serbian journalists are keeping up with information and achievements regarding COVID-19 vaccines constantly, in order to inform the public about every possible solution. They are particularly curious about the RocketVax COVID-19 vaccine development since the CEO of the company, Dr. Vladimir Cmiljanovic, was born and raised in Serbia.

He gave many interviews for the Serbian press; you can read some of them by clicking on the files below:

RTS_RocketVax                                 Serbian_Times_RocketVax                                        Dnevno_RocketVax

Sources: RTS, Serbian Times & Dnevno



22 April 2021

Watson: “A Swiss ‘Super Vaccine’ plans to save the world from COVID-19”

There is light at the end of the tunnel. Progress is being made in vaccines against SARS-CoV-2, if somewhat slowly, particularly in Switzerland. They promise a return to normality, though they are not without setbacks. The vector vaccines developed by AstraZeneca and Johnson & Johnson are under fire following cases of thrombosis in younger women. […]

21 April 2021

CEO of RocketVax, Dr. Vladimir Cmiljanovic, spoke to SRF 1 radio about next generation SARS-CoV-2 vaccine, RVX-13

Dr. Vladimir Cmiljanovic, CEO of RocketVax, gave an interview to Swiss SRF 1 radio about the progress of RVX-13 – a second-generation SARS-CoV-2 vaccine: Source: SRF 1 Radio The most important differences between RVX-13, RocketVax’s SARS-CoV-2 vaccine, and the first-generation vaccines are as follows: 1. RVX-13 induces a comprehensive activation of the immune system. Unlike […]

20 April 2021

Serbian “Telegraf” is reporting about RocketVax’s SARS-CoV-2 vaccine

When the ongoing coronavirus pandemic broke out at the start of 2020, Swiss Rockets AG set itself the challenge of manufacturing a vaccine that activates multiple lines of immune system defense to combat SARS-CoV-2 most effectively. To achieve this mission, it founded the Basel-based subsidiary RocketVax AG in the summer of 2020. To start working […]

09 April 2021

How come China controls the pandemic so effectively? How will the second-generation of SARS-CoV-2 vaccine, RVX-13, provide long-lasting immunity?

CEO of RocketVax, Dr. Vladimir Cmiljanovic, explains for Kanal 5 TV Macedonia his opinion on how China has managed to control the pandemic rapidly and effectively. During the interview, Dr. Cmiljanovic also talked about the development of the second-generation SARS-CoV-2 vaccine, RVX-13, that will provide long-lasting immunity. “The first reason is that the socialist system […]

16 March 2021

RocketVax SARS-CoV-2 vaccine should be effective regardless of the mutation occurring on the spike protein

CEO of RocketVax, Dr. Vladimir Cmiljanovic, gave an interview about the development of the second-generation SARS-CoV-2 vaccine for RTS (Serbian Broadcasting Corporation). “The first-generation vaccines are focused on one of the virus’s proteins – the so-called spike protein. They train our immune system by exposing the coronavirus spike protein to our immune cells. The so […]